Prognostic Value of Trop-2 Expression in Nonmetastatic Triple-Negative Breast Cancer and Correlation With Emerging Biomarkers

Overview

Journal Cancer Med

Specialty Oncology

Date 2025 Mar 10

PMID 40059728

Authors

William Jacot

Marie-Christine Chateau

Simon Thezenas

Severine Guiu

Nelly Firmin

Virginie Lafont

Gwendal Lazennec

Charles Theillet

Florence Boissiere-Michot

Affiliations

Soon will be listed here.

Abstract

Introduction: Triple-Negative Breast Cancer (TNBC) is an aggressive breast cancer subtype, in which targeting the Trophoblast cell-surface antigen-2 (Trop-2), using antibody-drug conjugates (ADC), results in significant clinical improvement. However, clinicopathological correlations with Trop-2 protein expression levels remain limited in TNBC patients.

Methods: Here we assessed by immunohistochemistry (IHC) using the mouse monoclonal anti-Trop-2 antibody (Enzo, Cat. ENZ-ABS380) cell membrane Trop-2 expression levels and classified them in 3 H-Score classes, low (< 100), moderate (100-200), and strong (> 200). We also evaluated potential associations with clinicopathological variables including basal-like and molecular apocrine phenotypes, immune infiltrate characteristics, PTEN and PIK3CA alterations in a large retrospective series of 228 nonmetastatic TNBC patients.

Results: Trop-2 expression was evaluated as low, moderate and strong in 12.3%, 28.9%, and 58.8% of the cases respectively. Only 3 tumors showed no Trop-2 expression. Interestingly, Trop-2 expression was not associated with classical breast cancer clinicopathological variables, HER2 levels or molecular subtype, neither did we observe an association with relapse-free survival. Only a marginal association with pT1 tumors was observed, which tended to express increased levels of Trop-2 protein. In order to determine possible fluctuations of Trop-2 protein expression levels during the course of the disease, we studied a second independent cohort of 18 TNBC comprised of serial tissue samples (diagnostic biopsies, surgical resection specimens and corresponding patients-derived xenografts (PDX)). Trop-2 levels remained globally stable between cognate tumor samples with only one exception corresponding to a Trop-2-negative tumor giving rise to a Trop-2-positive PDX.

Conclusions: As Trop-2 expression appears nearly constant and independent of classical TNBC variables and outcome, association of anti-Trop-2 therapies with other targeted therapies can be evaluated without reducing the population in specific TNBC subgroups.

References

Elias A . Triple-negative breast cancer: a short review. Am J Clin Oncol. 2009; 33(6):637-45. DOI: 10.1097/COC.0b013e3181b8afcf. View

Zhao W, Kuai X, Zhou X, Jia L, Wang J, Yang X . Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol Rep. 2018; 40(2):759-766. DOI: 10.3892/or.2018.6496. View

Vidula N, Yau C, Rugo H . Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast Cancer Res Treat. 2022; 194(3):569-575. DOI: 10.1007/s10549-022-06660-x. View

Guiu S, Mollevi C, Charon-Barra C, Boissiere F, Crapez E, Chartron E . Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. Br J Cancer. 2018; 119(1):76-79. PMC: 6035246. DOI: 10.1038/s41416-018-0142-6. View

Du Manoir S, Orsetti B, Bras-Goncalves R, Nguyen T, Lasorsa L, Boissiere F . Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. Mol Oncol. 2014; 8(2):431-43. PMC: 5528550. DOI: 10.1016/j.molonc.2013.11.010. View

Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T . Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021; 20(12):2329-2340. PMC: 9398094. DOI: 10.1158/1535-7163.MCT-21-0206. View

Lehmann B, Pietenpol J . Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2013; 232(2):142-50. PMC: 4090031. DOI: 10.1002/path.4280. View

Bardia A, Hurvitz S, Tolaney S, Loirat D, Punie K, Oliveira M . Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021; 384(16):1529-1541. DOI: 10.1056/NEJMoa2028485. View

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

10.

Boissiere-Michot F, Jacot W, Massol O, Mollevi C, Lazennec G . CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers. Cancers (Basel). 2021; 13(10). PMC: 8151934. DOI: 10.3390/cancers13102328. View

11.

Bardia A, Tolaney S, Punie K, Loirat D, Oliveira M, Kalinsky K . Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021; 32(9):1148-1156. DOI: 10.1016/j.annonc.2021.06.002. View

12.

Lenart S, Lenart P, Smarda J, Remsik J, Soucek K, Benes P . Trop2: Jack of All Trades, Master of None. Cancers (Basel). 2020; 12(11). PMC: 7696911. DOI: 10.3390/cancers12113328. View

13.

Carey L, Dees E, Sawyer L, Gatti L, Moore D, Collichio F . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-34. DOI: 10.1158/1078-0432.CCR-06-1109. View

14.

Boissiere-Michot F, Chabab G, Mollevi C, Guiu S, Lopez-Crapez E, Ramos J . Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer. Cancers (Basel). 2021; 13(4). PMC: 7918092. DOI: 10.3390/cancers13040765. View

15.

Jacot W, Mollevi C, Fina F, Lopez-Crapez E, Martin P, Colombo P . High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. BMC Cancer. 2015; 15:986. PMC: 4683760. DOI: 10.1186/s12885-015-1977-3. View

16.

Lehmann B, Jovanovic B, Chen X, Estrada M, Johnson K, Shyr Y . Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6):e0157368. PMC: 4911051. DOI: 10.1371/journal.pone.0157368. View

17.

Jacot W, Maran-Gonzalez A, Massol O, Sorbs C, Mollevi C, Guiu S . Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers. Cancers (Basel). 2021; 13(23). PMC: 8656488. DOI: 10.3390/cancers13236059. View

18.

Jeon Y, Jo U, Hong J, Gong G, Lee H . Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. BMC Cancer. 2022; 22(1):1014. PMC: 9509625. DOI: 10.1186/s12885-022-10076-7. View

19.

Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, Simeone P . Trop-2 is a determinant of breast cancer survival. PLoS One. 2014; 9(5):e96993. PMC: 4019539. DOI: 10.1371/journal.pone.0096993. View

20.

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View